J
Julien Taieb
Researcher at University of Paris
Publications - 482
Citations - 11958
Julien Taieb is an academic researcher from University of Paris. The author has contributed to research in topics: Colorectal cancer & Medicine. The author has an hindex of 50, co-authored 409 publications receiving 8679 citations. Previous affiliations of Julien Taieb include Paris Descartes University & French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
Dendritic cell derived-exosomes: biology and clinical implementations
Nathalie Chaput,Caroline Flament,Sophie Viaud,Julien Taieb,Stephan Roux,Alain Spatz,Fabrice Andre,Jean-Bernard LePecq,Muriel Boussac,Jérôme Garin,Sebastian Amigorena,Clotilde Théry,Laurence Zitvogel +12 more
TL;DR: The potential of dendritic cell‐derived exosomes (Dex) as cell‐free cancer vaccines is addressed in this review and lessons learned from the pioneering clinical trials allowed reassessment of the priming capacities ofDex in preclinical models, optimizing clinical protocols, and delineating novel, biological features of Dex in cancer patients.
Journal ArticleDOI
Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials
Thierry André,Jeffrey A. Meyerhardt,Timothy Iveson,Alberto Sobrero,Takayuki Yoshino,Ioannis Souglakos,Axel Grothey,Donna Niedzwiecki,Mark P Saunders,Roberto Labianca,Takeharu Yamanaka,Ioannis Boukovinas,Dewi Vernerey,Jeffrey P. Meyers,Andrea Harkin,Valter Torri,Eiji Oki,Vassilis Georgoulias,Julien Taieb,Anthony F. Shields,Qiang Shi +20 more
TL;DR: Overall survival results support the use of 3 months of adjuvant CAPOX for most patients with stage III colon cancer, strengthened by the substantial reduction of toxicities, inconveniencies, and cost associated with a shorter treatment duration.
Journal ArticleDOI
Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab: A Post Hoc Analysis of the PETACC-8 Trial
Julien Taieb,Aziz Zaanan,Aziz Zaanan,Karine Le Malicot,C. Julié,Hélène Blons,Hélène Blons,Laurent Mineur,Jaafar Bennouna,Josep Tabernero,Enrico Mini,Gunnar Folprecht,Jean-Luc Van Laethem,Côme Lepage,Jean-François Emile,Pierre Laurent-Puig,Pierre Laurent-Puig +16 more
TL;DR: The prognostic value of BRAF and KRAS mutations in patients who have undergone resection for colon cancer and have been treated with combination leucovorin, fluorouracil, and oxaliplatin-based adjuvant chemotherapy is controversial, possibly owing to a lack of stratification on mismatch repair status.
Journal ArticleDOI
Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort
Alix Portal,Simon Pernot,David Tougeron,Claire Arbaud,Anne Thirot Bidault,Christelle De La Fouchardiere,Pascal Hammel,Thierry Lecomte,Johann Dreanic,Romain Coriat,Jean-Baptiste Bachet,Olivier Dubreuil,Lysiane Marthey,Laetitia Dahan,Belinda Tchoundjeu,Christophe Locher,Céline Lepère,Franck Bonnetain,Julien Taieb +18 more
TL;DR: Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort is presented.
Journal ArticleDOI
Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study.
Amani Asnacios,Laetitia Fartoux,Olivier Romano,Chloe Tesmoingt,Samy Louafi S,Touraj Mansoubakht,Pascal Artru,Thierry Poynard,Olivier Rosmorduc,Mohamed Hebbar,Julien Taieb +10 more
TL;DR: The authors conducted a phase 2 trial of the antiepidermal growth factor receptor (EGFR) monoclonal antibody cetuximab in combination with the gemcitabine plus oxaliplatin regimen in patients with documented progressive hepatocellular carcinoma (HCC).